New Therapy Significantly Extends Survival for Advanced Pancreatic Cancer Patients

An investigational targeted therapy, daraxonrasib, has demonstrated a substantial increase in median overall survival for individuals with previously treated metastatic pancreatic cancer. Results from a pivotal Phase 3 trial indicate a 60% reduction in the risk of death compared to standard chemotherapy. These findings, presented at a major medical conference and published in a prestigious journal, suggest a potential new standard of care for this challenging disease.